Item 7.01. Regulation FD Disclosure.

On October 9, 2021, Dennis Marcus, M.D., F.A.S.R.S., President, Southeast Retina Center, and a principal investigator for REGENXBIO Inc.'s (the "Company") Phase II ALTITUDE clinical trial utilizing in-office suprachoroidal delivery of RGX-314 for the treatment of diabetic retinopathy, presented an interim analysis of data from the ALTITUDE trial at the American Society of Retina Specialists Annual Meeting. A copy of Dr. Marcus' presentation materials is available on the "Presentations and Publications" section of the Company's website at www.regenxbio.com.

The information in Item 7.01 of this Current Report on Form 8-K and the presentation materials on the Company's website shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 8.01. Other Events.

On October 9, 2021, the Company issued a press release announcing an interim analysis of data from the ALTITUDE trial. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.




(d)  Exhibits



Exhibit No.       Description

99.1                Press release dated October 9, 2021.

104               The cover page from this Current Report on Form 8-K, formatted in
                  Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses